News articles about Intra-Cellular Therapies (NASDAQ:ITCI) have been trending positive on Tuesday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Intra-Cellular Therapies earned a news impact score of 0.30 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.1062114979018 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the headlines that may have effected Accern’s scoring:

A number of analysts have recently commented on the company. Zacks Investment Research upgraded Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research note on Tuesday, May 16th. Piper Jaffray Companies upgraded Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $14.00 to $33.00 in a research note on Thursday, September 7th. JMP Securities upgraded Intra-Cellular Therapies from a “market perform” rating to an “outperform” rating and set a $24.00 target price on the stock in a research note on Thursday, August 24th. ValuEngine upgraded Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a research note on Friday, August 18th. Finally, Cowen and Company restated an “outperform” rating and issued a $27.00 target price (up previously from $20.00) on shares of Intra-Cellular Therapies in a research note on Friday. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $27.11.

Shares of Intra-Cellular Therapies (NASDAQ ITCI) opened at 20.90 on Tuesday. The stock has a 50 day moving average price of $13.70 and a 200-day moving average price of $12.79. Intra-Cellular Therapies has a 52 week low of $7.85 and a 52 week high of $45.20. The stock’s market cap is $907.56 million.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.33. Intra-Cellular Therapies had a negative return on equity of 27.92% and a negative net margin of 32,834.94%. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.03 million. During the same quarter last year, the company posted ($0.71) earnings per share. The business’s revenue was down 52.2% on a year-over-year basis. Equities analysts predict that Intra-Cellular Therapies will post ($2.36) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/12/intra-cellular-therapies-itci-getting-positive-press-coverage-report-finds.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Insider Buying and Selling by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Stock Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related stocks with our FREE daily email newsletter.